A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02846506 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
DRUG: Canagliflozin 50 mg
DRUG: Canagliflozin 100 mg
DRUG: Metformin Extended Release (XR)

Sponsor

Janssen Research & Development, LLC